GLP1R and dementia: Pooled data from three randomized double‐blind placebo‐controlled cardiovascular outcome trials (15,820 patients) and a nationwide Danish registry‐based cohort (120,054 patients) showed lower dementia rate in patients randomized to GLP‐1 RAs versus placebo [38].